Skip to content
Screener

Protalix BioTherapeutics, Inc. PLX Q2 2026 earnings

Reported August 12, 2026 · Before market open

Revenue$19.9MBeat by $6.9M
EPS$0.05Beat by $0.06
Revenue estimate$13.0M
EPS estimate-$0.01

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$13.4M
EPS estimate-$0.02

FAQ

When did Protalix BioTherapeutics, Inc. report Q2 2026 earnings?
Protalix BioTherapeutics, Inc. (PLX) reported Q2 2026 earnings on August 12, 2026 before market open.
What were Protalix BioTherapeutics, Inc.'s Q2 2026 revenue and EPS?
Protalix BioTherapeutics, Inc. reported revenue of $19.9M and eps of $0.05 for Q2 2026.
Did Protalix BioTherapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $13.0M by $6.9M. EPS beat the consensus estimate of $-0.01 by $0.06.
How did Protalix BioTherapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 27.1% from $15.7M a year earlier and eps grew 2375.2% from $0.00.
Where can I find Protalix BioTherapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-094433) and the 10-Q periodic report (0001104659-26-094444) directly on SEC EDGAR. The filing index links above go to sec.gov.